The 0.76 Kilogram Question: Why Genetic Targeting of Ozempic Is Promising Science But a Dangerous Policy Lever

A study published today in Nature represents the largest pharmacogenomic investigation of GLP-1 drugs ever conducted. Researchers at the 23andMe Research Institute² analyzed 27,885 people who used semaglutide or tirzepatide and identified a missense variant in the GLP1R gene significantly associated with weight loss efficacy. The finding has already sparked breathless speculation about precision-prescribing Ozempic and Wegovy based on your DNA. I want to unpack why that speculation is mostly wrong, and why the real implications of this research are more troubling than exciting.

Let's start with the number that matters: 0.76 kilograms¹. That's the additional weight loss expected per copy of the effect allele. About 1.7 pounds. For people carrying two copies, Ruth Loos at the University of Copenhagen noted it was "more than 10 percent of the total weight loss"³ in the study population. That's a real signal. It replicates. It's biologically interesting. But it is nowhere near the magnitude required to support a commercially viable "precision tier" where identified responders pay a premium and insurers cover them preferentially. Think about what the optimistic precision medicine narrative requires. It needs a genetic biomarker that separates strong responders from non-responders clearly enough that a payer can say: "We'll pay $8,000 a year for this patient but not that one, because the genetic test tells us who benefits." The oncology model where this works — Herceptin for HER2-positive breast cancer, Keytruda for PD-L1 high tumors — depends on massive effect size differences. HER2-positive patients see dramatically different survival curves. GLP-1 response genetics, based on today's evidence, give us gradients, not categories.

This matches what we knew from earlier, smaller work. A 2023 Lancet Diabetes & Endocrinology⁴ genome-wide study found that combining the two most predictive GLP1R gene variants identified just 4% of the population with a 30% greater HbA1c reduction than the worst-responding 9%. A 30% relative difference sounds significant until you realize we're talking about the tails of the distribution — and the vast middle remains undifferentiated. A 2025 review in Expert Opinion on Pharmacotherapy⁵ put it bluntly: "Currently, we do not seem to have the right tools to effectively predict the response to GLP-1 RA."

So why does this matter commercially? Because the GLP-1 market is staggeringly large and economically stressed. U.S. spending on GLP-1 medicines now exceeds $70 billion annually⁶, yet approximately 50% of patients discontinue within 12 months. A JAMA Network Open cohort study⁷ of 125,474 patients found that 64.8% of those without type 2 diabetes stopped their GLP-1 within a year. That's an enormous amount of waste — patients who tried an expensive drug, didn't respond or couldn't tolerate it, and churned off. Companies like PrecisionLife and Ovation⁶ are already marketing "payor-facing tests" to predict GLP-1 response. The commercial interest is real and accelerating.

I think the case for using genetic information to guide GLP-1 prescribing is genuinely promising as a scientific research program. The problem is how this information enters the insurance system. And here, the optimistic story — that better patient selection will improve cost-effectiveness and expand payer willingness to cover the drug — collides with how American health insurance actually works.

Consider the current landscape. ICER's December 2025 final evidence report⁸ found injectable semaglutide cost-effective at its current net price of $6,829 per year, with an incremental cost-effectiveness ratio of $61,400 per QALY⁹. That's well within standard thresholds. Yet ICER simultaneously warned that "fewer than 1% of eligible adults" could be treated before exceeding budget impact thresholds. The drugs are cost-effective individually but unaffordable collectively. Medicare still cannot cover GLP-1s for weight loss alone¹⁰ — the Trump administration declined to finalize the Biden-era rule change in April 2025. The BALANCE Model¹¹ launching via a bridge demonstration in July 2026 represents a partial workaround, offering $50/month copays to eligible Medicare beneficiaries, but it's voluntary and its durability is uncertain. Only 13 state Medicaid programs¹² covered GLP-1s for obesity as of January 2026, down from 16 in 2025.

This is the environment into which genetic stratification data arrives. Payers who are already looking for reasons to limit GLP-1 spending don't need genetic non-responder classifications to deny coverage — they're denying it now. But the genetic data changes the quality of the denial in ways that matter. A broad cost-effectiveness denial is a policy decision, contestable through political pressure and new evidence (the SELECT trial's cardiovascular data is the paradigmatic example). An individualized genetic non-responder classification is a clinical determination attached to your specific genome. It's much harder to contest, and — critically — it comes framed as being for the patient's benefit. The insurer isn't denying coverage because the drug is expensive; they're denying it because your genes say it won't work for you.

Is this prohibited by GINA (the Genetic Information Nondiscrimination Act)? Not clearly. GINA prohibits health insurers from using genetic information for eligibility or premium-setting decisions¹³. But the Department of Labor's own FAQs¹⁴ explicitly state that a health plan can condition payment for a service "based on medical appropriateness" when "the medical appropriateness depends on the genetic makeup of the patient." The plan can even "refuse payment in that situation if the patient does not undergo the genetic test." This is a wide-open door for using companion diagnostics as gatekeeping tools, and it exists right now in current regulatory guidance.

The strongest counterargument to my concern is that precision prescribing reduces waste and could improve the cost-effectiveness profile enough to expand coverage for identified responders. There's logic to this. If you could show an insurer that genetically screened patients achieve, say, 85% clinically meaningful weight loss versus 50% in unscreened populations, the QALY math improves dramatically for that subgroup. But today's evidence shows effect sizes far too small for that. The 23andMe GWAS found a statistically significant but modest association. The broader predictive models combining genetic, demographic, and clinical factors showed ability to stratify — but stratification at the population level is not the same as confident individual-level prediction that justifies denying treatment.

The patent picture adds another layer. Novo Nordisk's core semaglutide compound patent expires in December 2031 in the U.S.¹⁵, with at least 13 generic companies¹⁶ already expressing interest to the FDA. A proprietary companion diagnostic — a patented genetic test that determines who should get the drug — would constitute an independent IP asset, potentially extending Novo Nordisk's commercial moat well beyond patent expiry of the molecule itself. I-MAK's analysis¹⁷ documented that Novo Nordisk has filed 320 U.S. patent applications and been granted 154 patents related to its semaglutide products. The incentive to develop and patent a companion diagnostic is structurally obvious, and it has little to do with patient outcomes.

I think the honest assessment is this: genetic pharmacogenomics of GLP-1 drugs is real science producing real findings. The 23andMe Nature paper is good work. But the effect sizes are too small to support a commercially viable precision tier, and the regulatory gap in GINA creates a real path for insurers to use genetic data as a denial mechanism. The people most likely to be harmed by this are the same people already struggling to access these drugs — lower-income patients without robust insurance coverage, who disproportionately bear the burden of obesity.

Here's what to watch. If Novo Nordisk or Eli Lilly files patents on a companion diagnostic test for GLP-1 response prediction in the next 12-18 months, that's the clearest signal that the precision-medicine pivot is primarily an IP strategy. If ICER or CMS begins incorporating genetic stratification into coverage determinations before the effect sizes support individual-level prediction, that's the clearest signal that the exclusion mechanism is outrunning the science. And if the PrecisionLife/Ovation Phase II collaboration⁶, now scaling to 25,000 patients, produces a validated biomarker that can reliably separate strong from weak responders with a differential exceeding 1.5x — that changes my analysis entirely, and I'll say so. But based on everything we know today, genetic targeting of GLP-1 drugs is a sharpening knife in a room full of people who don't need better tools for cutting patients off.